Last reviewed · How we verify
IL-17A antibody
IL-17A antibody is a Anti-IL-17 monoclonal antibody Biologic drug developed by Genrix (Shanghai) Biopharmaceutical Co., Ltd.. It is currently in Phase 2 development for Psoriasis, Plaque psoriasis.
IL-17A antibody targets the IL-17A receptor
IL-17A antibody targets the IL-17A receptor Used for Psoriasis, Plaque psoriasis.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | IL-17A antibody |
|---|---|
| Sponsor | Genrix (Shanghai) Biopharmaceutical Co., Ltd. |
| Drug class | Anti-IL-17 monoclonal antibody |
| Target | IL-17A |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
IL-17A is a pro-inflammatory cytokine, and blocking its action can reduce inflammation in various conditions.
Approved indications
- Psoriasis
- Plaque psoriasis
Common side effects
- Nausea
- Headache
- Injection site reaction
Key clinical trials
- Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS (PHASE3)
- A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy (PHASE3)
- Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients (PHASE4)
- Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa (PHASE4)
- A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris. (PHASE1, PHASE2)
- Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis (NA)
- Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients. (PHASE1, PHASE2)
- A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IL-17A antibody CI brief — competitive landscape report
- IL-17A antibody updates RSS · CI watch RSS
- Genrix (Shanghai) Biopharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about IL-17A antibody
What is IL-17A antibody?
How does IL-17A antibody work?
What is IL-17A antibody used for?
Who makes IL-17A antibody?
What drug class is IL-17A antibody in?
What development phase is IL-17A antibody in?
What are the side effects of IL-17A antibody?
What does IL-17A antibody target?
Related
- Drug class: All Anti-IL-17 monoclonal antibody drugs
- Target: All drugs targeting IL-17A
- Manufacturer: Genrix (Shanghai) Biopharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Psoriasis
- Indication: Drugs for Plaque psoriasis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing